gemfibrozil

medtigo

gemfibrozil

Brand Name :

lopid

Synonyms :

gemfibrozil

Class :

Fibric acid agents

Action and Spectrum

Mechanism of action

It is a lipid-lowering agent used to treat hyperlipidaemia and primary dysbetalipoproteinemia. The mechanism of action of gemfibrozil is the inhibition of the synthesis of very low-density lipoproteins (VLDL) in the liver, leading to an increase in the elimination of VLDL and decreased plasma levels of triglycerides.

Spectrum

The spectrum of activity of gemfibrozil is mainly limited to decreasing triglycerides and increasing high-density lipoprotein (HDL) levels, and a lesser extent decreasing low-density lipoprotein (LDL) levels. It is ineffective in lowering cholesterol levels in patients with homozygous familial hypercholesterolemia.

Dosing & Uses

Drug Interaction

Adverse Reaction

Frequency defined:

>10%

Dyspepsia

1-10%

Atrial fibrillation

Fatigue

Eczema

Vertigo

Headache

Abdominal pain

Diarrhea

Rash

constipation

<1%

Rhabdomyolysis

Cholelithiasis

Hypokalemia

Myopathy

Taste disturbance

Flatulence

Myalgia

Acute appendicitis

Angioedema

Eosinophilia

Synovitis

Xerostomia

Rash

Black Box Warning

Contraindication / Caution

Contraindications

It is contraindicated in individuals with a known hypersensitivity to the drug.
It should be used with caution in patients with severe liver or renal disease, as these conditions may impair the elimination of the drug and increase the risk of toxicity.
Patients with primary biliary cirrhosis should not take gemfibrozil as it has been associated with gallstone formation in this population.
Patients with pre-existing gallbladder disease may also be at increased risk for gallstone formation with gemfibrozil use, and it may be necessary to monitor these patients closely.
Coadministration of gemfibrozil with repaglinide, simvastatin, selexipag, or dasabuvir is not recommended, as it may increase the risk of serious muscle injury (rhabdomyolysis)

Caution

Liver or renal disease: It should be used with caution in patients with liver or renal disease, as these conditions may impair the elimination of the drug and increase the risk of toxicity.
Hypersensitivity: It is contraindicated in individuals with a known hypersensitivity to the drug.
Gallbladder disease: Patients with pre-existing gallbladder disease may be at increased risk for gallstone formation with gemfibrozil use, and it may be necessary to monitor these patients closely.
Drug interactions: Coadministration of gemfibrozil with repaglinide, simvastatin, selexipag, or dasabuvir is not recommended, as it may increase the risk of serious muscle injury (rhabdomyolysis).
Myopathy has been associated with an increased risk of myopathy (muscle weakness or pain), mainly when used with other lipid-lowering agents.
Pregnancy and lactation: It should be used with caution in pregnant women and during lactation, as its safety in these populations has not been established.
Geriatrics: Geriatric patients may be at increased risk for adverse events with gemfibrozil use, and it may be necessary to monitor these patients closely

Pregnancy / Lactation

Pregnancy consideration: It should be used with caution in pregnant women, as its safety in these populations has not been established

Lactation: Excretion of the drug in human breast milk is unknown

Pregnancy category:

Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.

Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.

Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.

Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.

Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.

Category N: There is no data available for the drug under this category

Pharmacology

Pharmacology

It has multiple mechanisms of action to decrease lipid levels in the blood. It inhibits peripheral lipolysis, decreases the hepatic uptake of free fatty acids, which may, in turn, inhibit the secretion of very low-density lipoprotein (VLDL), and may also increase high-density lipoprotein (HDL) cholesterol, although the mechanism for this increase is not fully understood.

Pharmacodynamics

The main pharmacodynamic effect of gemfibrozil is to decrease levels of triglycerides and very low-density lipoprotein (VLDL) in the blood, improving the lipid profile. This is achieved by inhibiting the synthesis of VLDL in the liver, decreasing the hepatic uptake of free fatty acids, and increasing the elimination of VLDL.

In addition, gemfibrozil may increase high-density lipoprotein (HDL) levels, although the exact mechanism for this increase still needs to be fully understood.

Pharmacokinetics

Absorption: It is well absorbed from the gastrointestinal tract, with a peak serum time of 1-2 hours after oral administration.

Distribution: It is highly protein bound (99%) and distributes into tissues, including the liver and fat.

Metabolism: It undergoes extensive enterohepatic circulation, which is metabolized in the liver and reabsorbed in the small intestine.

Excretion/Elimination: The half-life of gemfibrozil is approximately 1.5 hours. It is excreted primarily in the urine (70%) and to a lesser extent in the feces (6%)

Adminstartion

Administration

It is administered orally in the form of a tablet. The recommended adult dose is 600 mg twice daily, taken with meals.

It is important to note that gemfibrozil should not be crushed, chewed, or broken before swallowing, as this may lead to an increased risk of adverse events.

In addition, gemfibrozil should be used with a diet low in saturated fat and cholesterol and a program of regular exercise to optimize lipid-lowering efficacy.

The dose of gemfibrozil may need to be adjusted based on individual patient factors, such as age, liver or kidney function, and other medical conditions or medications.

Patient Information Leaflet

Patient information leaflet

Generic Name: gemfibrozil

Pronounced: [ jem-FYE-broe-zil ]

Why do we use gemfibrozil?

It is used in the treatment of hyperlipidemia and primary dysbetalipoproteinemia

gemfibrozil

No data available for drug.

DRUG INTERACTION

gemfibrozil

&

gemfibrozil +

Contraindicated

Serious Use Alternative

Monitor Closely

Minor

gemfibrozil

No data available for drug.

DRUG INTERACTION

gemfibrozil

&

gemfibrozil +

Contraindicated

Serious Use Alternative

Monitor Closely

Minor

medtigo

gemfibrozil

Brand Name :

Synonyms :

Class :

Action and Spectrum

Dosing & Uses

Drug Interaction

Adverse Reaction

Black Box Warning

Contraindication / Caution

Pregnancy / Lactation

Pharmacology

Adminstartion

Patient Information Leaflet

CONTACT INFORMATION

ADDRESS

JOIN THE FASTEST GROWING HEALTHCARE COMMUNITY!

Download our APP

CONTACT INFORMATION

ADDRESS

Taking the Pain out of Your Career

DOWNLOAD APP